Amylyx Pharmaceuticals (AMLX) Cash from Investing Activities (2021 - 2026)

Amylyx Pharmaceuticals' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at $36.3 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 183.06% year-over-year to $36.3 million; the TTM figure through Mar 2026 stood at $94.0 million (up 201.39% YoY), while the FY2025 annual figure was $14.0 million, down 81.44% from the prior year.
• Cash from Investing Activities was $36.3 million for Q1 2026 at Amylyx Pharmaceuticals, up from $29.5 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $123.2 million in Q2 2023 to a low of -$228.2 million in Q4 2022.
• Historically, Cash from Investing Activities has averaged -$1.2 million across 5 years, with a median of $20.9 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities tumbled 709264.29% in 2022, then surged 2661.59% in 2023.
• A 5-year view of Cash from Investing Activities shows it stood at -$228.2 million in 2022, then surged by 109.17% to $20.9 million in 2023, then soared by 210.54% to $65.0 million in 2024, then plunged by 54.65% to $29.5 million in 2025, then grew by 23.06% to $36.3 million in 2026.
• The last three Cash from Investing Activities figures came in at $36.3 million (Q1 2026), $29.5 million (Q4 2025), and $5.2 million (Q3 2025), per Business Quant data.